SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $13,875.85 in Stock

Key Points

• Insider sale: Well Daan Van sold 2,861 shares on April 8 at an average of $4.85 for $13,875.85 under a pre-arranged Rule 10b5-1 plan to cover tax withholding from vested equity, leaving him with 350,808 shares (a 0.81% ownership decline).
• Financials and stock performance: SOPHiA GENETICS reported a ($0.28) EPS miss (revenue $21.71M slightly above expectations) and has negative margins and ROE; the stock trades near $4.70 with a market cap of $321.9M and a 1-year range of $2.58–$5.70.
• Market sentiment: Analysts carry a consensus "Hold" with a $7.00 target (two Buys, one Sell), and institutional investors own about 31.59% of the company after several new positions were reported.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) insider Well Daan Van sold 2,861 shares of the firm's stock in a transaction that occurred on Wednesday, April 8th. The stock was sold at an average price of $4.85, for a total transaction of $13,875.85. Following the transaction, the insider directly owned 350,808 shares in the company, valued at approximately $1,701,418.80. This trade represents a 0.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Well Daan Van also recently made the following trade(s):

• On Thursday, April 9th, Well Daan Van sold 1,988 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.74, for a total value of $9,423.12.
• On Monday, April 6th, Well Daan Van sold 2,705 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.86, for a total value of $13,146.30.
• On Thursday, March 19th, Well Daan Van sold 684 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.79, for a total value of $3,276.36.

SOPHiA GENETICS Trading Down 0.6%

SOPH traded down $0.03 during trading on Friday, hitting $4.70. 94,702 shares of the stock were exchanged, compared to its average volume of 184,971. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.84 and a current ratio of 1.96. The firm has a 50 day simple moving average of $4.76 and a 200 day simple moving average of $4.68. The firm has a market cap of $321.90 million, a price-to-earnings ratio of -9.22 and a beta of 1.04. SOPHiA GENETICS SA has a 1 year low of $2.58 and a 1 year high of $5.70.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last issued its earnings results on Tuesday, March 3rd. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.08). The firm had revenue of $21.71 million during the quarter, compared to analysts' expectations of $21.20 million. SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%. As a group, equities analysts expect that SOPHiA GENETICS SA will post -0.96 EPS for the current year.

Institutional Investors Weigh In On SOPHiA GENETICS

A number of institutional investors have recently added to or reduced their stakes in the stock. Alta Wealth Advisors LLC purchased a new position in SOPHiA GENETICS in the third quarter valued at about $6,708,000. Polen Capital Management LLC purchased a new stake in shares of SOPHiA GENETICS during the fourth quarter valued at about $102,000. Susquehanna International Group LLP purchased a new stake in shares of SOPHiA GENETICS during the third quarter valued at about $88,000. XTX Topco Ltd bought a new stake in shares of SOPHiA GENETICS in the 4th quarter valued at about $55,000. Finally, Quadrature Capital Ltd bought a new stake in shares of SOPHiA GENETICS in the 4th quarter valued at about $54,000. Institutional investors own 31.59% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Guggenheim boosted their price target on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the company a "buy" rating in a report on Monday, January 26th. Weiss Ratings reiterated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research note on Thursday, January 22nd. Finally, BTIG Research reissued a "buy" rating and set a $7.00 price objective on shares of SOPHiA GENETICS in a report on Tuesday, March 3rd. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $7.00.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.